Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Bausch Health Companies Inc. (T:BHC)

Business Focus: Pharmaceuticals (NEC)

This company is also listed in the United States as BHC on the NYSE. Click here to get the live US quote and see if there are any SEC insider filings..
Oct 04, 2021 07:05 am ET
Clearside Biomedical Announces Multiple Poster Presentations at the Retina Society 54th Annual Scientific Meeting
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple presentations...
Aug 04, 2021 06:55 am ET
May 05, 2021 06:55 am ET
Health Canada Issues Notice of Compliance (NOC) for Bausch Health's BRYHALI™
LAVAL, QC, May 5, 2021 /CNW Telbec/ - Bausch Health, Canada, which is part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), ("Bausch Health" or the "Company") today announced that Health Canada has approved the use of BRYHALI (Halobetasol Propionate Lotion 0.01% w/w), a high to super-high potency topical corticosteroid indicated for Corticosteroid-Responsive Dermatoses and the topical treatment of plaque psoriasis.i Some of the most "commonly-encountered skin disorders under the Corticosteroid-Responsive Dermatoses umbrella include seborrheic dermatitis and eczematous dermatoses such
May 03, 2021 07:05 am ET
Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the resubmission of its New...
Feb 08, 2021 07:05 am ET
Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that numerous clinical...
Dec 01, 2020 05:55 am ET
Bausch + Lomb Announces Additional Expanded Public Coverage for (Pr)VYZULTA® (Latanoprostene Bunod Ophthalmic Solution 0.024% w/w) in Canada
PrVYZULTA® Added Under British Columbia, North West Territories, the Yukon and Veteran Affairs Plans LAVAL, QC, Dec. 1, 2020 /CNW/ - Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC), announced that PrVYZULTA® (latanoprostene bunod ophthalmic solution, 0.024% w/w), which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertensioni, now has expanded public drug program reimbursement in Canada in the jurisdictions of British Columbia, North West Territories, the Yukon and Veteran Aff
Nov 10, 2020 05:55 am ET
Bausch Health, Canada Receives a Positive Recommendation from the CADTH Canadian Drug Expert Committee (CDEC) for DUOBRII™ - a Novel Topical Antipsoriatic Prescription Drug
DUOBRII is a topical antipsoriatic medication introduced in Canada1 Positive CADTH recommendation moves DUOBRII closer to federal, provincial and territorial drug plan reimbursement DUOBRII provides the combined action of two compounds, halobetasol propionate, a corticosteroid, and tazarotene, a retinoid prodrug1 Formulated with PRISMATREX™, a proprietary technology, DUOBRII lotion improves the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis1 DUOBRII is manufactured for distribution throughout Canada and the United States at the Company's Que
Oct 20, 2020 06:55 am ET
Emerade™ (epinephrine 0.3 mg and 0.5 mg) now available in Canada
For the first time, Canadians managing emergency anaphylaxis have a new option with Emerade 0.5 mg dose auto-injector
Oct 13, 2020 07:00 am ET
Eyenovia to Host Investor Call to Discuss Recent Licensing Agreements Resulting in Total Potential License Payments and Development Cost Reimbursement and Savings of Approximately $100 Million
Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that management will host an investor conference call to discuss the company’s...
Sep 24, 2020 07:00 am ET
Bausch + Lomb Announces Expanded Public Coverage for (Pr)VYZULTA® (Latanoprostene Bunod Ophthalmic Solution 0.024% w/w) in Canada
PrVYZULTA® Added Under Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Newfoundland and Labrador, and Federal Non-Insured Health Benefits (NIHB) Plans LAVAL, QC, Sept. 24, 2020 /CNW Telbec/ - Bausch + Lomb., a leading global eye health business of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), announced that PrVYZULTA® (latanoprostene bunod ophthalmic solution, 0.024% w/w), which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertensioni, now has expanded public drug program reimbursement in the provinces of A
Sep 23, 2020 07:05 am ET
Clearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE™ Data in Diabetic Macular Edema in Ophthalmology Retina
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today several clinical data...
Sep 02, 2020 06:55 am ET
Now Available in Canada - Bausch Health, Canada Launches First of its Kind, Topical Antipsoriatic Agent in Almost Twenty Years
Formulated with PRISMATREX™, a proprietary technology, DUOBRII™ lotion improves the signs and symptoms of plaque psoriasis in adult patients with moderate to severe plaque psoriasis.
Jun 11, 2020 07:00 am ET
Health Canada Issues Notice of Compliance for Bausch Health's DUOBRII™
TOPICAL COMBINATION IMPROVING THE SIGNS AND SYMPTOMS OF PLAQUE PSORIASIS IN ADULT PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS FORMULATED WITH PROPRIETARY PRISMATREX™ TECHNOLOGY i
Dec 19, 2019 03:01 pm ET
Bausch + Lomb Announces VYZULTA® (Latanoprostene Bunod Ophthalmic Solution 0.024%) Now Publicly Covered Under the Ontario Public Drug Benefit (ODB) Program
LAVAL, QC, Dec. 19, 2019 /CNW Telbec/ - Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), today announced that VYZULTA® (latanoprostene bunod ophthalmic solution, 0.024%), which is indicated  for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertensioni, will be  listed as a limited use product under the Ontario Drug Benefit (ODB) Formulary.ii The product will be added to formulary on Dec. 20, 2019. 
Dec 13, 2019 04:15 pm ET
Oct 28, 2019 04:01 pm ET
Ahead of World Psoriasis Day, Bausch Health, Canada announces that SILIQ® (brodalumab) is now covered on most drug benefit formularies in Canada
Decision by majority of provincial governments to publicly list the drug ensures improved treatment access for nearly 800,000 Canadians currently living with plaque psoriasis1,2
Oct 17, 2019 10:15 am ET
Bausch Health Announces Updated Health Canada Safety Information for ELIDEL®
TOPICAL ATOPIC DERMATITIS TREATMENT, ELIDEL® NOW AVAILABLE FOR CHILDREN THREE MONTHS AND OVER
Apr 25, 2019 01:29 pm ET
IIROC Trade Resumption - BHC
TORONTO, April 25, 2019 /CNW/ - Trading resumes in:
Apr 25, 2019 01:16 pm ET
IIROC Trading Halt - BHC
TORONTO, April 25, 2019 /CNW/ - The following issues have been halted by IIROC:
Jan 08, 2019 06:30 am ET
Bausch Health's Canadian business positioned for growth in 2019
LAVAL, QC, Jan. 8, 2019 /CNW Telbec/ - Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) is positioned for growth in Canada in 2019 under a new name, Bausch Health, Canada inc. with a strong pipeline of products and a well-established manufacturing presence in the country.
Jan 03, 2019 06:30 am ET
Bausch + Lomb Announces HEALTH CANADA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution, 0.024%) for the Treatment of Glaucoma
LAVAL, QC, Jan. 3, 2019 /CNW Telbec/ - Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health (NYSE : BHC) (TSX : BHC) today announced that on December 27, 2018, Health Canada issued the Notice of Compliance (NOC) for VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%). VYZULTA™, the first prostaglandin analog with one of its metabolites being Nitric Oxide (NO), is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.i VYZULTA™ is the first new innovative treatment for open-angle
Sep 27, 2018 07:45 am ET
Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)
Dova Pharmaceuticals, Inc. (“Dova”) (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, and Salix Pharmaceuticals (“Salix”), one of...
Aug 20, 2018 07:00 am ET
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-106, an Encapsulated Bowel Preparation
RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it has received a...